JAMA Clinical Evidence Synopsis
April 14, 2015

FDG-PET/CT Imaging for Mediastinal Staging in Patients With Potentially Resectable Non–Small Cell Lung Cancer

Author Affiliations
  • 1National Collaborating Centre for Cancer, Wales, United Kingdom
  • 2Department of Respiratory Medicine, Nottingham University Hospitals National Health Service Trust, Nottingham City Hospital, United Kingdom
  • 3Queen Mary University, London, United Kingdom
  • 4Clinical Biostatistics Unit, Institute Ramon y Cajal of Health Research and Biomedical Research Networking Centre, Cochrane Collaborating Centre, Madrid, Spain

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;313(14):1465-1466. doi:10.1001/jama.2015.2365

Clinical Question  What is the sensitivity and specificity of 18F-fludeoxyglucose–positron emission tomography/computed tomography (FDG-PET/CT) imaging for detecting mediastinal lymph node involvement in patients with potentially resectable non–small cell lung cancer (NSCLC)?

Bottom Line  Sensitivity and specificity of FDG-PET/CT imaging ranged from 0.77 to 0.81 for sensitivity and 0.79 to 0.90 for specificity, and were related to the brand of scanner, NSCLC subtype, FDG dose, and country of study origin. These sensitivities and specificities are not sufficiently accurate to warrant reliance on FDG-PET/CT scanning alone to make decisions about surgery as a single option for patients with potentially resectable NSCLC. Instead FDG-PET/CT imaging should be used to determine whether the next step should be biopsy (endobronchial ultrasound–guided biopsy or mediastinoscopy) or surgical resection.